Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy

Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy

Journal Pre-proof Diagnostic Performance of Three-Dimensional Thickness of Endothelium/Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy T...

30MB Sizes 0 Downloads 34 Views

Journal Pre-proof Diagnostic Performance of Three-Dimensional Thickness of Endothelium/Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy Taher Eleiwa, MD, MSc, Amr Elsawy, MSc, Mohamed Tolba, MD, William Feuer, Sonia Yoo, MD, Mohamed Abou Shousha, MD, PhD PII:

S0161-6420(20)30046-4

DOI:

https://doi.org/10.1016/j.ophtha.2020.01.021

Reference:

OPHTHA 11078

To appear in:

Ophthalmology

Received Date: 25 July 2019 Revised Date:

6 January 2020

Accepted Date: 10 January 2020

Please cite this article as: Eleiwa T, Elsawy A, Tolba M, Feuer W, Yoo S, Shousha MA, Diagnostic Performance of Three-Dimensional Thickness of Endothelium/Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy, Ophthalmology (2020), doi: https://doi.org/10.1016/j.ophtha.2020.01.021. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2020 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46

Title: Diagnostic Performance of Three-Dimensional Thickness of Endothelium/Descemet Complex in Fuchs’ Endothelial Cell Corneal Dystrophy Authors: Taher Eleiwa, MD, MSc1,2, Amr Elsawy, MSc1,3, Mohamed Tolba, MD1,5, William Feuer,1 Sonia Yoo, MD1, Mohamed Abou Shousha MD, PhD1,3,4 1 Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL 2 Department of Ophthalmology, Faculty of Medicine, Benha University, Egypt 3 Electrical and Computer Engineering, University of Miami, Miami, FL. 4 Biomedical Engineering, University of Miami, Miami, FL. 5 International medical center, Egyptian Armed Forces, Cairo, Egypt Corresponding Author: Mohamed Abou Shousha, MD, FRSC, PhD Bascom Palmer Eye Institute University of Miami Miller School of Medicine 900 NW 17 Street Miami, Florida 33136 [email protected] Declarations: • Ethics approval and consent to participate: This study was approved by the University of Miami Institutional Review Board. • Availability of data and material: The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. • Keywords: Optical coherence tomography, Descemet’s membrane, corneal endothelium, Fuchs endothelial dystrophy. List of Abbreviations: • FECD: Fuchs’ endothelial Corneal Dystrophy; En/DM: Endothelium-Descemet’s complex; En/DMT: Endothelium-Descemet’s complex thickness; TCT: total corneal thickness; HD-OCT: High-definition Optical Coherence Tomography; AS-OCT: Anterior segment Optical Coherence Tomography; ROC: Receiver Operating Characteristics; AUC: Area under curve; PK: Penetrating keratoplasty; EK: Endothelial Keratoplasty; DSAEK: Descemet Stripping Automated Endothelial Keratoplasty; SD: standard deviation; GEE: Generalized Estimating Equations; 2D: two-dimensional; 3D: three-dimensional. Conflicts of Interest and Source of Funding: Taher Eleiwa, Amr Elsawy, William Feuer and Mohamed Tolba- None to declare Sonia Yoo and Mohamed Abou Shousha: United States Non-Provisional Patents (Application No. 8992023 and 61809518), and PCT/US2018/013409. Patents and PCT are owned by University of Miami and licensed to Resolve Ophthalmics, LLC. Mohamed Abou Shousha and Sonia Yoo are equity holders and sit on the Board of Directors for Resolve Ophthalmics, LLC, and are consultants of Avedro. Sonia H. Yoo is a consultant of CARL Zeiss Meditec and Dompe. Financial Support: This study was supported by a NEI K23 award (K23EY026118), NEI core center grant to the University of Miami (P30 EY014801), and Research to Prevent Blindness (RPB). The funding organization had no role in the design or conduct of this research. Authors' contributions: All authors attest that they meet the current ICMJE criteria for Authorship. Running head: Regional Analysis of Endothelium/Descemet’s membrane Thickness in Fuchs’ Dystrophy

47

Abstract

48

Purpose: To describe the diagnostic accuracy of the regional three-dimensional (3D)

49

endothelium/Descemet’s membrane complex thickness (En/DMT) in Fuchs’ endothelial corneal

50

dystrophy (FECD), and to determine its potential role as an objective index of disease severity.

51

Design: Observational case-control study.

52

Participants: 104 eyes of 79 subjects (64 eyes of 41 FECD patients, and 40 eyes of 38 healthy

53

age- and gender-matched controls).

54

Methods: All participants were imaged using HD-OCT device (Envisu R2210, Bioptigen,

55

Buffalo Grove, IL, USA). FECD was clinically classified into early (without edema) and late-

56

stage (with edema). Automatic and manual segmentation of the corneal layers was performed

57

using a custom-built segmental tomography algorithm to generate 3D-thickness maps of total

58

cornea thickness (TCT) and En/DMT of the central 6 mm cornea. Regional En/DMT, regional

59

TCT, and central to peripheral total corneal thickness ratio (CPTR) were evaluated and

60

correlated to the clinical severity of the disease. Intraclass Correlation Coefficients (ICC), and

61

Bland-Altman plots were used to assess the reliability of the repeated measurements in all eyes.

62

Main Outcome Measures: CPTR, average En/DMT and TCT of central, paracentral and

63

peripheral regions.

64

Results: In FECD, there was a significant increase in En/DMT, CPTR, and TCT as compared to

65

controls (P < 0.001). For identifying FECD, average En/DMT of paracentral and peripheral

66

regions achieved 94% sensitivity and 100% specificity (Cutoffs, 19 µm and 20 µm, respectively),

67

while CPTR had 94% sensitivity with a specificity of 73% (Cutoff, 0.97). For discriminating

68

early-stage FECD from controls, average En/DMT of central zones achieved 92% sensitivity and

69

97% specificity (Cutoff, 18 µm), while CPTR had 90% sensitivity and 88% specificity (Cutoff,

70

0.97). The average En/DMT of central, paracentral and peripheral regions was highly correlated

71

with FECD clinical stage (Spearman’s rho = 0.813, 0.793, and 0.721; all P < 0.001,

72

respectively), compared to (0.672 and 0.481; P < 0.001) for CPTR and mean TCT of paracentral

73

zones, respectively. ICC values ranged from 0.98 (En/DMT) to 0.99 (TCT) with a good

74

agreement between the automatic and manual measurements.

75

Conclusion: Regional 3D-En/DMT is a novel diagnostic tool of FECD that can be used to

76

quantify the disease severity with excellent reliability.

77

Introduction

78

Fuchs endothelial corneal dystrophy (FECD) is one of the most common indications of

79

corneal transplantation.1-5 FECD is defined as a progressive bilateral asymmetric disease of the

80

corneal endothelium characterized by endothelial cell loss, endothelial barrier disruption,

81

thickening of the Descemet’s membrane (DM), and formation of excrescences known as guttae

82

that may result in corneal edema and decreased vision.6 When penetrating keratoplasty (PK) was

83

considered the only treatment for FECD, traditional grading of the disease, based on the presence

84

of clinically detectable corneal edema and extent of guttae, was appropriate. However, the recent

85

progress in the surgical and non-surgical interventions for FECD, makes the accurate diagnosis

86

of FECD before the development of irreversible ultrastructural changes in the host tissue

87

paramount to the best visual outcomes.7-9 Therefore, future trials for FECD should include

88

measures of endothelial morphology, endothelial function, and visual impact regardless of the

89

intervention.5

90

The current diagnostic tools, including slit lamp examination (SLE), corneal pachymetry,

91

specular microscopy and confocal microscopy, fall short of detecting the natural course of the

92

disease or predicting its progression, especially after cataract surgery. Although subjective

93

clinical evaluation using SLE might be the gold standard, SLE does not account for the presence

94

of subclinical edema.10 Regarding pachymetry, isolated measurement of central corneal thickness

95

and corneal volume is not always representative of corneal edema or disease severity.10 Repp et

96

al. described the relative central to peripheral corneal thickening in two meridians, but it is not

97

always effective to assess the extent of the disease.10 Furthermore, potential sampling errors with

98

narrow-field specular and confocal microscopy, and regional variations between guttate areas

99

and visible cells render the corneal measurements inaccurate.11, 12 Recently, Sun et al. reported a

100

new classification of FECD severity by evaluating pachymetry map and posterior corneal

101

curvature patterns measured with Scheimpflug tomography.4 They reported loss of parallel

102

isopachs in ≤42% of FECD eyes without clinical edema compared to ≥81% in FECD eyes

103

suspicious for corneal edema.4 However, they also reported the presence of the tomographic

104

features of interest in 7% of the control eyes. Thus, it is important to consider coexisting subtle

105

corneal pathologies prior to interpreting the tomographic maps.4, 5

106

Previously, Abou Shousha et al. used high-definition optical coherence tomography (HD-

107

OCT) to characterize endothelium/Descemet’s membrane complex (En/DM) and to measure its

108

central thickness in FECD.13 It is also worth mentioning that these measurements were two-

109

dimensional (2D), hence, were not representative of the whole cornea and can easily miss an

110

ongoing pathology. In this study, we used an automated custom-built segmental tomography

111

algorithm to segment the corneal boundaries and generate three-dimensional (3D) thickness

112

maps of endothelium/Descemet’s membrane complex (En/DMT), and total corneal thickness

113

(TCT) from the captured HD-OCT images of the central 6-mm cornea. Compared to manual

114

segmentation, this algorithm has been proven to be able to automatically segment all corneal

115

layers in healthy and pathological corneas with as good as accuracy, though with significantly

116

less time and significantly better repeatability as well.14, 15 Using 3D-thickness maps, we

117

compared the diagnostic performance of regional En/DMT, regional TCT, and the quotient of

118

mean central TCT and mean peripheral TCT at 4-6 mm from the center (CPTR) between FECD

119

corneas with variable severity to healthy age-matched controls. Moreover, we determined the

120

relationship between these parameters and disease severity.

121 122

Materials and Methods:

123

Study design and participants

124

This study was approved by the University of Miami Institutional Review Board. All

125

participants provided written informed consent before enrollment. The study design complied

126

with the Health Insurance Portability and Accountability Act (HIPAA), and followed the tenets

127

of the Declaration of Helsinki for biomedical research.

128

One hundred and four eyes of 79 individuals (64 clinically diagnosed FECD eyes, and 40

129

healthy controls) were prospectively and consecutively recruited from June 2018 to September

130

2019 at Bascom Palmer Eye Institute, University of Miami. FECD was diagnosed clinically by

131

the presence of central or paracentral guttae, with or without clinically detectable edema. Eyes

132

were either phakic or pseudophakic with a posterior chamber intraocular lens implant in the

133

capsular bag in the studied groups, without any history of ocular inflammation. Subjects were

134

excluded from the study if they had glaucoma, ocular hypertension, inflammatory eye diseases,

135

ocular surface diseases, and systemic diseases with ocular involvement. In addition, we excluded

136

patients with history of ocular surgery (except uneventful cataract surgery with endocapsular

137

intraocular lens insertion at least 6 months prior to enrollment), contact lens wear, and the use of

138

topical medications (except artificial tears) or systemic medications that could affect the cornea.

139

Because of the asymmetrical nature of the disease between the two eyes of the same patient, all

140

FECD eyes were included unless an exclusion criterion was detected. Slit lamp examination was

141

performed on each eye by a masked cornea specialist in order to assign and the examined cornea

142

into either a healthy cornea or FECD. Moreover, FECD eyes were clinically graded at the slit-

143

lamp according to the following guidelines: grade 1: non-confluent guttae; grade 2: presence of

144

any area of confluent guttae, but without clinical edema; grade 3: confluent guttae with clinical

145

edema; grade 4: edema associated with whitening or haze.16 We categorized early-stage FECD as

146

grade 1 and 2 and late-stage FECD as grade 3 and 4.12 Clinical progression was defined as a

147

subsequent decision to proceed to endothelial keratoplasty (EK) based on occurrence of

148

clinically evident edema associated with visual impairment reported by the patient.4 Later HD-

149

OCT imaging and thickness measurements were reviewed if available.

150

Test methods

151

Image Acquisition and Analysis

152

Anterior segment high-definition optical coherence tomography (HD-OCT; Envisu

153

R2210, Bioptigen, Buffalo Grove, IL, USA) was performed to each participant, using a 6 mm

154

radial scan pattern centered on the corneal vertex. This device has an axial optical resolution of 3

155

µm, a transversal width of 6 mm, a corrected depth of 1.58 mm using the approximate refractive

156

index for the whole cornea of 1.376,17 and a scanning speed of 32,000 A-scans per second. Each

157

participant was asked to look at a central fixation target and the presence of a visible specular

158

reflection in all images of the scan confirmed an optimal centration.18, 19 Then, a custom-built

159

segmental tomography algorithm was utilized to automatically segment the corneal epithelium,

160

Descemet’s membrane and the endothelium. Then, an experienced and masked observer (TE)

161

manually corrected the automated segmentation of images from corneas with late-stage FECD

162

because the pathological changes in the disease reduce the accuracy of segmenting the En/DM

163

boundary by the automated method. In addition, manual segmentation was performed twice by a

164

masked trained manual operator [MT] to test the intra-operator repeatability and compare the

165

automatic and manual measurements to determine the accuracy of the algorithm. Elsawy et al.

166

had described and validated this algorithm against 5 trained manual operators by measuring the

167

reproducibility between the manual operators, the reproducibility between the manual and

168

automatic methods, and the repeatability of the automatic and manual methods. Additionally, a

169

subjective test was performed by 2 corneal specialists to assess both the manual and automatic

170

measurements. They disclosed that the automatic measurements were comparable to the manual

171

ones with significantly higher repeatability and less running time per image.14 Random Sample

172

Consensus (RANSAC)20 method with a polynomial model was used to estimate the corneal layer

173

boundaries from candidate boundary points obtained from thresholding the OCT image followed

174

by flattening the corneal layers and subsequent vertical projection to detect relative locations of

175

Descemet's layer from the endothelium (Figure 1).14 Then, bi-cubic interpolation of the

176

segmented different frames of the scan is used to reconstruct the surfaces of the corneal layers.21

177

Finally, the inter-surface distances were corrected using 3D ray-tracing algorithm by applying

178

the vector form of Snell’s law at the interface between each 2 consecutive layers to generate the

179

average 3D thickness values in each region of the bulls-eye map (Figure 2-a).22, 23 The 6 mm

180

bulls-eye map was divided into 14 regions; 2 central, 6 paracentral and 6 peripheral (figure 2-b).

181

The mean thickness of the central, paracentral and peripheral regions was calculated and used for

182

further analysis.

183

Diagnostic indices

184

Central, paracentral, and peripheral En/DMT were compared to the corresponding

185

regional TCT using the 3D-thickness maps. Using custom-built segmental tomography

186

algorithm, thickness values are the measured inter-surface distances, in the OCT reflectivity

187

profile, between the endothelial and Descemet’s membrane peaks for En/DMT, and between the

188

epithelial and the endothelial peaks for TCT (Figure 1). Besides, CPTR was calculated as the

189

quotient of the mean central TCT and the mean peripheral TCT at 4-6 mm zone from the center

190

(Table 1).

191

Statistical Analysis

192

Statistical analyses were performed using SPSS software version 22.0 (SPSS, Chicago,

193

IL, USA). Continuous data were summarized with means and standard deviations while

194

dichotomous data were summarized with proportions. Comparisons between groups were

195

performed using Generalized Estimating Equations (GEE) methods to account for the correlation

196

between two eyes of the same patient.24 Residuals of the fitted models were examined to assess

197

model performance and Box-Cox methods were used to identify appropriate transformations to

198

effect normality for significance testing when necessary.25

199

The sensitivity and specificity of regional En/DMT, CPTR and TCT in differentiating

200

between studied groups were determined by generating receiver operating characteristic curves

201

(ROC). In addition to area under ROC curves (AUCs), we have provided for each parameter

202

sensitivities and specificities, and the parameter cutoffs used to create them. To facilitate

203

comparisons between parameters, we chose the cutoffs that provided maximum diagnostic

204

accuracy for each parameter. For the objective assessment of FECD severity, Spearman rho

205

correlation coefficients were used to quantify correlations between thickness parameters and the

206

subjective clinical severity of the disease. Pearson correlations between regional En/DMT and

207

CPTR were also calculated. Two-sided p-values less than 0.05 were considered to be statistically

208

significant.

209

We summarized the reliability of manually segmented measurements with the intraclass

210

correlation coefficient (ICC).26 An ICC <0.4 constitutes poor agreement, an ICC >0.75

211

constitutes excellent reliability, while an ICC between 0.4 and 0.7 represents fair to good

212

reliability.26 Agreement between automated and manually segmented measurements was

213

assessed with the Bland-Altman method.27 The two manual segmentations were averaged for the

214

Bland-Altman analyses.

215

Results:

216

Participants

217

Our study included 104 eyes of 79 participants; the breakdown included 64 eyes of 41

218

FECD patients, and 40 eyes of 38 healthy subjects of similar age and gender. Three dimensional-

219

En/DM thickness maps were successfully generated from all included eyes.

220

Test Results

221

Manually segmented measurements demonstrated excellent reliability for both En/DMT

222

and TCT with ICCEn/DMT=0.98 and ICCTCT=0.99. Figure 3 displays the Bland-Altman plot of

223

automated versus manual measurements for En/DMT and TCT. Regarding En/DMT, the Bland-

224

Altman Limits of Agreement (LOA) ranged from -1.2 to +1.3, about 5% of the range of

225

measurement. There was no systematic difference between the two techniques (mean = 0.02,

226

paired t-test P=0.74) and no evidence of a differential effect related to measurement magnitude.

227

For TCT, the Bland-Altman results were similar with LOA ranging from -3.6 to 3.4, about 4% of

228

the range of measurement. Similarly, there was no systematic difference between techniques

229

(mean = -0.1, paired t-test P=0.57) and no evidence of a differential effect with measurement

230

magnitude.

231

Table 2 summarizes the different characteristics of both groups. With the exception of

232

peripheral TCT, there were highly significant differences between healthy and FECD eyes in

233

TCT and En/DMT measurements. Accounting for pseudophakia in these analyses did not change

234

the results (Figure 4). Table 3 compares early with late-stage FECD. Age was not statistically

235

significant in any of the models (P >0.4). Late-stage FECD eyes had significantly higher central

236

TCT and En/DMT in all locations than did early-stage eyes (P ranging from 0.048 to <0.001).

237

CPTR did not differ significantly between stages.

238

The qualitative and quantitative differences between the healthy and FECD corneas are

239

demonstrated in figure 5. In healthy eyes, the En/DM layer was visualized in the HD-OCT as a

240

band formed by 2 smooth regular hyper-reflective lines with a hypo-reflective space in between.

241

On the other hand, the posterior line had a wavy irregular appearance with areas of focal

242

thickenings in FECD corneas. Using 3D-thickness maps, En/DMT, central TCT and CPTR were

243

significantly higher in FECD group compared to controls (P<0.001, Table 2).

244

Table 4 summarizes the diagnostic performance of regional En/DMT, CPTR, and TCT.

245

For identifying FECD, En/DMT parameters had specificity of 100% and sensitivity ≥92%, while

246

TCT parameters had specificity of 73% with sensitivities ranging from 77% to 94%. For

247

discriminating between healthy and early-stage disease, En/DMT parameters had specificity

248

>92% with sensitivity of 92%, while TCT parameters had specificities ranging from 59% to 88%

249

with sensitivities ranging from 80% to 90% (Figure 6, Table 4).

250

Objective assessment of FECD severity determined by central En/DMT, paracentral

251

En/DMT and peripheral En/DMT showed stronger correlations with subjective clinical grading,

252

(Spearman’s rho = 0.813, 0.793, and 0.721; all P < 0.001respectively), compared to Spearman’s

253

rho = 0.672 and 0.481 for CPTR and paracentral TCT, respectively (all P <0.001). Peripheral

254

En/DMT was highly correlated with CPTR (R=0.721, P<0.001, Figure 7).

255

During the consultation at which HD-OCT images were acquired, 25 late-stage FECD

256

eyes were recommended to have EK. All of them had thicker En/DMT than both healthy and

257

early-stage FECD eyes. Of the 39 early-stage FECD eyes, ≥6 months follow-up data were

258

available for 14 eyes. No eyes were recommended for EK during the initial consultation at which

259

HD-OCT images were acquired. Within the next 14 months, 1 eye was recommended to have

260

DSAEK due to the development of clinically evident edema and subjective visual impairment

261

(Figure 8).

262

Discussion:

263

FECD is a disease of the corneal endothelium with secondary changes in Descemet’s

264

membrane, stroma, sub-basal nerve plexus and the epithelium.28 Ex-vivo studies after corneal

265

transplantation, in FECD eyes, showed that Descemet’s membrane thickening, guttae, and

266

abnormal endothelium were correlating to clinical corneal edema.6, 13, 29 A better understanding

267

of these changes might help determine when and how to intervene, especially as newer

268

treatments enable earlier intervention.9, 30, 31 Currently, with the advent of HD-OCT, it has

269

become possible to carry out non-invasive in-vivo imaging to analyze the corneal microstructure

270

at a quasi-histologic level.15, 32 However, there is still a gap bringing this technology to the

271

clinical practice due to the lack of automated analysis software for rapid and accurate

272

quantification of corneal layers with high repeatability.33 To address this gap, our group has

273

developed and validated an automated custom-built algorithm to segment OCT B-scans,

274

reconstruct the 3D corneal surfaces using bicubic interpolation, and subsequently generate the

275

3D thickness maps.14, 15 Our findings support that 3D-En/DMT has the highest sensitivity and

276

specificity in diagnosing and grading FECD. Excellent reliability was found for repeated

277

measures of TCT and En/DMT, with a good agreement between both manual and automatic

278

methods.

279

Clinical diagnosis of FECD is rarely in doubt, but clinical grading of the disease severity

280

is highly confusing,10 suggesting that a more objective metric of severity is mandated. The wide

281

variation in the normal TCT complicates its use, especially, to detect subclinical edema at one

282

point in time.10, 34 Besides, corneal thickness is not constant and can be expected to vary when it

283

is measured at different times of the day.35 Using pachymetry, Repp et al. described the CPTR as

284

an objective index to assess the disease severity.10 However, that meridional CPTR can miss a

285

focal paracentral edema, thus, not always effective in evaluating the severity of the disease.

286

Previously, Abou Shousha et al. had described the cross-sectional central En/DMT in FECD

287

using manual measurement, but they were not able to highlight peripheral localized changes that

288

could be earlier signs of the disease secondary to the 2D measurement. In our study, we used the

289

generated 3D-thickness maps, from HD-OCT scans, to compare the diagnostic performance of

290

regional En/DMT, regional TCT, and calculated CPTR in FECD. This more objective 3D-

291

thickness analysis is more robust than the 2D measurements, since the data are interpreted from a

292

larger region of the cornea rather than only 2 meridians; thus, it is less susceptible to missing

293

minor changes in the optical scan.17 Moreover, we used the peripheral regional thickness as an

294

internal reference when measuring central thickness in the same cornea to highlight the relative

295

central corneal swelling in early disease.10, 36 In FECD, all regional En/DMT, central TCT, and

296

paracentral TCT were significantly higher than normal, while the TCT in the peripheral 4-6 mm

297

zone of the map was not. Based on the area under the ROC curves, 3D-En/DMT parameters

298

provided excellent detection of FECD, followed by 3D-CPTR. In this cohort, age had no

299

significant impact on En/DMT. However, it should be noted that controls and FECD patients

300

recruited for our study were all elderly. Thus, the impact of age on En/DMT in our study might

301

be limited to this age group and not essentially representative of younger subjects.

302

Although there was a very strong positive correlation between increasing subjective

303

grade and regional En/DMT, this relationship between the regional En/DMT and clinical grade

304

should be interpreted with caution, because this subjective grading may not be the ideal method

305

to quantify the severity, and it is credible that corneas with mild edema could be on the threshold

306

of requiring a corneal transplant. Hence, we investigated the objective relationship between the

307

3D-En/DMT and 3D-CPTR; we found the strongest positive correlation for the peripheral

308

En/DMT, followed by paracentral En/DMT and central En/DMT. This correlation could be an

309

indirect indicator of disease progression, suggesting that regional En/DMT changes possibly

310

before the onset of a clinically evident increase in corneal thickness. This study was not able to

311

identify the exact chronological changes in the En/DM, but we hypothesize that these changes

312

might occur before, and contribute to the secondary subclinical edema (Figure 7).

313

Our study is not without limitations. First, although encouraging, the present results stem

314

from a limited number of patients; however, our study demonstrates a substantial, statistically

315

significant ability to discriminate between healthy eyes and FECD eyes as well as healthy and

316

early FECD (Table 4). In this context, we have included the cutoff values and 95% confidence

317

intervals around the AUCs for further studies to replicate our results and bring this tool into

318

clinical practice. Second, imaging was limited to the central 6 mm of the cornea as the tele-

319

centric probe has a reduced axial resolution and signal intensity in peripheral regions.37 Third,

320

the segmental tomography used in the present study significantly contributed to a better

321

characterization of the En/DM complex in FECD eyes; however, possible concomitant changes

322

in Bowman’s layer and the corneal epithelium were not evaluated. Future studies are required to

323

explore the tomographic features of these layers in FECD. The cross-sectional nature of our

324

study is another limitation, thus the long-term changes in En/DM with advancing FECD weren’t

325

examined. Further, the possibility that cases of mild edema were misclassified as the labeling of

326

FECD into early and late stages was reliant on clinically evident edema using slit-lamp

327

examination. Future studies using more objective labelling parameters such as those reported by

328

Sun et al. using Scheimpflug tomography are required not to misclassify mild disease.4

329

Moreover, time of the HD-OCT imaging was not standardized in this cohort and this may

330

contribute to the slightly lower performance TCT based measurements. It has been reported that

331

afternoon central TCT measures were lower compared to values acquired from early morning;38,

332

39

333

observed within their subject groups over the working day40, 41. Interestingly, the slightly higher

334

performance of CPTR in this study could be attributed to the relative central swelling in FECD

335

corneas,36 contrasted with the relative peripheral thickening in healthy ones42. Further studies

336

are required to explore the effect of diurnal variations on the diagnostic performance of both

337

regional TCT and En/DMT in FECD. Finally, we presented quantitative regional analysis of

338

TCT and En/DMT, but we could not address the functional status of the endothelium. Hence,

339

future prospective, longitudinal larger studies using wider field segmental tomography of all

340

corneal layers are warranted to do so.

however, others noted that no time-dependent difference in central TCT measures were

341

In summary, our study disclosed the three-dimensional En/DMT maps as a potential

342

objective diagnostic tool that can be used to grade the severity of FECD in addition to CPTR

343

obtained from the three-dimensional TCT maps and more subjective modalities such as

344

morphological grading. The concurrent increase in En/DMT in early-stage FECD may

345

potentially interact with endothelial function and subsequently play a role in the development of

346

corneal edema. A strong correlation between En/DMT values and FECD severity points to the

347

potential utility of En/DMT in guidance of treatment decisions and prediction for surgical

348

intervention. Finally, further studies by other teams are needed to replicate these results in their

349

own patient populations and allow to objectively distinguish healthy corneas, corneas with guttae

350

but no edema from FECD cases, and from the subclinical edema as well.

351

352

References

353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372

1. Gain P, Jullienne R, He Z, et al. Global Survey of Corneal Transplantation and Eye Banking. JAMA Ophthalmol. 2016;134(2):167-73. 2. Hsu KM, Chang SH, Brothers W, et al. Indications for Keratoplasty at 3 academic centers from 2002 to 2012. Eye Contact Lens. 2016;42(6):374-9. 3. Ghosheh FR, Cremona FA, Rapuano CJ, et al. Trends in penetrating keratoplasty in the United States 1980–2005. Int Ophthalmol. 2008;28(3):147-53. 4. Sun SY, Wacker K, Baratz KH, Patel SV. Determining Subclinical Edema in Fuchs Endothelial Corneal Dystrophy: Revised Classification using Scheimpflug Tomography for Preoperative Assessment. Ophthalmology. 2019;126(2):195-204. 5. Patel SV. Towards Clinical Trials in Fuchs Endothelial Corneal Dystrophy: Classification and Outcome Measures—The Bowman Club Lecture 2019. BMJ Open Ophthalmol. 2019;4(1):e000321. 6. Rodrigues MM, Krachmer JH, Hackett J, et al. Fuchs' corneal dystrophy: a clinicopathologic study of the variation in corneal edema. Ophthalmology. 1986;93(6):789-96. 7. Van der Meulen IJ, Patel SV, Lapid-Gortzak R, et al. Quality of vision in patients with fuchs endothelial dystrophy and after descemet stripping endothelial keratoplasty. Arch Ophthalmol 2011;129(12):1537-42. 8. Koizumi N, Okumura N, Ueno M, et al. Rho-associated kinase inhibitor eye drop treatment as a possible medical treatment for Fuchs corneal dystrophy. Cornea. 2013;32(8):1167-70. 9. Huang MJ, Kane S, Dhaliwal DK. Descemetorhexis Without Endothelial Keratoplasty Versus DMEK for Treatment of Fuchs Endothelial Corneal Dystrophy. Cornea. 2018;37(12):1479-83.

373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420

10. Repp DJ, Hodge DO, Baratz KH, et al. Fuchs' endothelial corneal dystrophy: subjective grading versus objective grading based on the central-to-peripheral thickness ratio. Ophthalmology. 2013;120(4):687-94. 11. McLaren JW, Bachman LA, Kane KM, Patel SV. Objective assessment of the corneal endothelium in Fuchs' endothelial dystrophy. Invest Ophthalmol Vis Sci. 2014;55(2):1184-90. 12. Aggarwal S, Cavalcanti BM, Regali L, et al. In Vivo Confocal Microscopy Shows Alterations in Nerve Density and Dendritiform Cell Density in Fuchs’ Endothelial Corneal Dystrophy. Am J Ophthalmol. 2018;196:136-44. 13. Shousha MA, Perez VL, Wang J, et al. Use of Ultra-High-Resolution Optical Coherence Tomography to Detect In Vivo Characteristics of Descemet's Membrane in Fuchs' Dystrophy. Ophthalmology. 2010;117(6):1220-7. 14. Elsawy A, Abdel-Mottaleb M, Sayed I-O, et al. Automatic Segmentation of Corneal Microlayers on Optical Coherence Tomography Images. Transl Vis Sci Technol. 2019;8(3):39. 15. Eleiwa TK, Cook JC, Elsawy AS, et al. Diagnostic Performance of Three-Dimensional Endothelium/Descemet's Membrane Complex Thickness Maps in Active Corneal Graft Rejection. Am J Ophthalmol. 2019. doi: 10.1016/j.ajo.2019.10.022. 16. Adamis AP, Filatov V, Tripathi BJ, Tripathi RC. Fuchs' endothelial dystrophy of the cornea. Surv Ophthalmol. 1993;38(2):149-68. 17. Yadav R, Kottaiyan R, Ahmad K, Yoon G. Epithelium and Bowman's layer thickness and light scatter in keratoconic cornea evaluated using ultrahigh resolution optical coherence tomography. J Biomed Opt. 2012;17(11):116010. 18. Huang D. Future direction of anterior segment optical coherence tomography. Anterior Segment Optical Coherence Tomography. 2008:165-72. 19. Abou Shousha M, Yoo SH, Sayed MS, et al. In Vivo Characteristics of Corneal Endothelium/Descemet Membrane Complex for the Diagnosis of Corneal Graft Rejection. Am J Ophthalmol. 2017;178:27-37. 20. Fischler MA, Bolles RC. Random sample consensus: a paradigm for model fitting with applications to image analysis and automated cartography. Communications of the ACM 24.6 (1981): 381-395. 21. Han D. Comparison of commonly used image interpolation methods. Proceedings of the 2nd International Conference on Computer Science and Electronics Engineering: Atlantis Press, 2013. 22. Zhao M, Kuo AN, Izatt JA. 3D refraction correction and extraction of clinical parameters from spectral domain optical coherence tomography of the cornea. Optics Express. 2010;18(9):8923-36. 23. P. A. Handbook of Visual Optics: CRC Press, 2017. 24. Ying G-s, Maguire MG, Glynn R, Rosner B. Tutorial on biostatistics: linear regression analysis of continuous correlated eye data. Ophthalmic epidemiol. 2017;24(2):130-40. 25. Box GE, Hunter WG, Hunter JS. Statistics for experimenters. John Wiley & Sons, Inc. 1978:23940. 26. Fleiss JL. Design and analysis of clinical experiments. Vol. 73: John Wiley & Sons. 2011. 27. Martin Bland J, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. The Lancet. 1986;327(8476):307-10. 28. Zhang J, Patel DV. The pathophysiology of Fuchs' endothelial dystrophy – A review of molecular and cellular insights. Exp Eye Res. 2015;130:97-105. 29. Alomar TS, Al-Aqaba M, Gray T, et al. Histological and confocal microscopy changes in chronic corneal edema: implications for endothelial transplantation. Invest Ophthalmol Vis Sci. 2011;52(11):8193-207. 30. Kim EC, Meng H, Jun AS. Lithium treatment increases endothelial cell survival and autophagy in a mouse model of Fuchs endothelial corneal dystrophy. Br J Ophthalmol. 2013;97(8):1068-73.

421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445

31. Okumura N, Koizumi N, Kay EP, et al. The ROCK inhibitor eye drop accelerates corneal endothelium wound healing. Invest Ophthalmol Vis Sci. 2013;54(4):2493-502. 32. Ang M, Baskaran M, Werkmeister RM, et al. Anterior segment optical coherence tomography. Prog Retin Eye Res. 2018;66:132-56. 33. Ang M, Chong W, Huang H, et al. Comparison of anterior segment optical tomography parameters measured using a semi-automatic software to standard clinical instruments. PLoS One. 2013;8(6):e65559. 34. Kopplin LJ, Przepyszny K, Schmotzer B, et al. Relationship of Fuchs endothelial corneal dystrophy severity to central corneal thickness. Arch Ophthalmol. 2012;130(4):433-9. 35. Doughty MJ, Zaman ML. Human Corneal Thickness and Its Impact on Intraocular Pressure Measures: A Review and Meta-analysis Approach. Surv Ophthalmol. 2000;44(5):367-408. 36. Brunette I, Sherknies D, Terry MA, et al. 3-D characterization of the corneal shape in Fuchs dystrophy and pseudophakic keratopathy. Invest Ophthalmol Vis Sci. 2011;52(1):206-14. 37. Podoleanu A, Charalambous I, Plesea L, et al. Correction of distortions in optical coherence tomography imaging of the eye. Phys Med Biol. 2004;49(7):1277. 38. Hirji N, Larke J. Thickness of human cornea measured by topographic pachometry. Am J Optom Physiol Opt. 1978;55(2):97-100. 39. Fujita S. Circadian rhythm of human corneal thickness (author's transl). Nippon Ganka Gakkai Zasshi. 1980;84(9):1232. 40. Bron A, Chapard J, Creuzot-Garcher C, et al. Is corneal thickness measurement reliable and useful? J Fr Ophtalmol. 1999;22(2):160-8. 41. Wolfs RC, Klaver CC, Vingerling JR, et al. Distribution of central corneal thickness and its association with intraocular pressure: The Rotterdam Study. Am J Ophthalmol. 1997;123(6):767-72. 42. Read SA, Collins MJ. Diurnal Variation of Corneal Shape and Thickness. Optom Vis Sci. 2009;86(3):170-80.

446 447

Legends:

448

Figure 1-a: High-definition optical coherence tomography image of a cornea with Fuchs

449

Endothelial Corneal Dystrophy (FECD). The presence of specular reflection (SR) confirms

450

adequate centration. The preset shows a magnified image of the posterior part of the

451

corresponding cornea with the red arrows pointing at Descemet’s membrane (DM), and the blue

452

arrows at the corneal endothelium (En). Bars are 100 µm.

453

Figure 1-b: Segmental tomography of the OCT image in Figure 1-a after flattening of the

454

corneal epithelium (Epi) and corneal endothelium (En). Right upper preset shows a magnified

455

image of the anterior part of the flattened cornea with the blue line representing the segmented

456

anterior boundary of the corneal epithelium (Epi). The left lower preset shows a magnified image

457

of the posterior part of the corresponding cornea with the red dashed line representing the

458

segmented Descemet’s membrane (DM), and the blue line for the segmented corneal

459

endothelium (En).

460

Figure 1-c: Vertical projection of the OCT scan lines after flattening of the corneal layers to

461

create a reflectivity profile of the OCT image in figure 1-a. The first and last peaks correspond to

462

the epithelial (Epi) and endothelial boundaries, respectively. Descemet's membrane (DM) was

463

localized as the most prominent peak just before the endothelial (En) peak.

464

Figure 2-a: A diagram illustrating the concept of using three-dimensional ray tracing to correct

465

the inter-surface distances and generate the thickness maps. The axial distances between the

466

initial surface and the uncorrected surfaces (black arrows) represent the optical path length and it

467

is converted to geometric distance (red dashed arrows) using the layer refractive index. Three-

468

dimensional ray tracing is used at each surface to correct for the refraction in the incident OCT

469

beam by utilizing a generalized vector implementation of Snell’s law at the refractive interface

470

between each 2 consecutive layers. Then, the thickness is measured as the shortest distance

471

between the initial surface and the corrected consecutive surfaces.

472

Figure 2-b: Bulls-eye map of the central 6 mm cornea showing the arrangement of regions for

473

quantitative analysis of the layer thickness: Central region (C1, C2) lies within a 2 mm diameter,

474

surrounded by 2 concentric paracentral (M1, M2, M3, M4, M5, M6) and outer (O1, O2, O3, O4,

475

O5, O6) rings, each with a 2 mm width. N: Nasal; S: Superior; T: Temporal; I: Inferior.

476

Figure 3: Bland-Altman plots of automatic versus manually segmented measurements for

477

endothelium/Descemet’s membrane complex thickness (En/DMT, left plot), and total corneal

478

thickness (TCT, right plot). The difference between the two measurements is represented against

479

the mean of them.

480

Figure 4: Box-plot distributions showing that there was no statistically significant effect of the

481

intraocular lens status (phakic versus pseudophakic) on the changes in the mean regional corneal

482

thickness, and median endothelium/Descemet’s membrane complex thickness values between

483

the studied groups. It also highlights that there is almost no overlap between FECD eyes and

484

healthy controls.

485

Figure 5: showing the qualitative and quantitative discrimination between late-stage Fuchs’

486

endothelial corneal dystrophy (A), early-stage Fuchs’ endothelial corneal dystrophy (B), and

487

healthy cornea (C) with the corresponding color-coded and bulls-eye maps of the three-

488

dimensional total corneal thickness (3D-TCT, left column) and endothelium/Descemet’s

489

membrane complex thickness (3D-En/DMT, right column). The presets show magnified images

490

of the posterior part of the corresponding cornea with the blue arrows pointing at Descemet’s

491

membrane (DM), and the yellow arrows at the corneal endothelium (En). In healthy cornea, the

492

En/DM layer was visualized in the HD-OCT as a band formed by 2 smooth regular hyper-

493

reflective lines with a hyporeflective space in between. In FECD, the posterior line had a wavy

494

irregular appearance with areas of focal thickenings. The bulls-eye and color-coded maps of the

495

regional TCT and En/DMT demonstrate the quantitative differences between the displayed eyes.

496

Note the excellent discrimination between the studied corneas using the 3D-En/DMT maps,

497

compared to the 3D-TCT maps.

498

Figure 6: Combined receiver operating characteristics (ROC) graph showing substantial increase

499

in the area under ROC curve using regional endothelial/Descemet's membrane complex

500

thickness (En/DMT) compared to regional total corneal thickness; and central to peripheral total

501

corneal thickness ratio (CPTR) in differentiating Fuchs Endothelial Corneal Dystrophy (FECD)

502

from healthy cornea (A) and early-stage FECD from healthy corneas (B).

503

Figure 7: The top raw shows scatter plots displaying that central, paracentral, and peripheral

504

endothelial/Descemet's membrane complex thickness (En/DMT) values have strong positive

505

correlation with the subjective clinical grading reported by Adamis et al.16 The bottom raw

506

shows scatter plots displaying that central, paracentral, and peripheral endothelial/Descemet's

507

membrane complex thickness (En/DMT) values have strong positive linear correlation with

508

central to peripheral total corneal thickness ratio (CPTR).

509

Figure 8: Three-dimensional total corneal thickness (3D-TCT) and endothelium/Descemet’s

510

membrane complex thickness (3D-En/DMT) maps of one eye with early-stage Fuchs Endothelial

511

Corneal Dystrophy (FECD) at the first visit (A) and after 14 months (B). At the first visit, the

512

cornea did not have clinically evident edema on slit-lamp examination (SLE) as shown in the

513

TCT map and OCT image, yet revealed significant thickening of En/DM complex (A). After 14

514

months, obvious edema was detected on SLE as shown in the OCT image with subjective visual

515

deterioration. The bulls-eye and color-coded maps demonstrate the progressive increase in both

516

regional TCT and En/DMT.

Table 1: Diagnostic indices

Diagnostic index Endothelial/Descemet’s Membrane Thickness (En/DMT) Total Corneal Thickness (TCT) Central to peripheral total corneal thickness ratio (CPTR)

Definition The measured inter-surface distance between the endothelial peak and Descemet’s membrane peak in the OCT reflectivity profile using custom-built segmental tomography algorithm. The measured inter-surface distance between the epithelial and the endothelial peaks in the OCT reflectivity profile using custom-built segmental tomography algorithm. The quotient of central TCT and peripheral TCT at 4-6 mm from the center.

FECD clinical grade9 Grade: N (%) of eyes

Phakic eyes Pseudophakic eyes (PC.IOL) Female Male

Number of eyes Gender

Healthy Group N=40

FECD Group N=64

--------------

24 (60%)

1: 18 (28%), 2: 21 (33%), 3: 11 (17%), 4: 14 (22%) 33 (52%)

16 (40%)

31 (48%)

19 (47%) 21 (53%)

40 (63%) 24 (37%)

65 (50-82) years Central TCT (µm) 521±31 Paracentral TCT (µm) 531±32 Peripheral TCT (µm) 548±35 0.95 (0.87CPTR 1.02) Central En/DMT (µm) 16 (15-18) Paracentral En/DMT (µm) 17 (15-19) Peripheral En/DMT (µm) 18 (16-20) Table 2: Characteristics of study groups Age (range) years



• •

69 (50-95) years 569±35 577±31 562±39 1.01 (0.941.08) 23 (17-38) 26 (17-37) 29 (20-40)

Difference between group means (95% CI)

Not applicable

p value

p = 0.449* p = 0.078*

4 (-1, +9)

p = 0.118**

48 (32, 63) 45 (31, 60) 13 (-4,+31) 0.06 (0.05, 0.07) 8 (7, 10) 9 (8, 10) 12 (10, 13)

p <0.001** p <0.001** p = 0.124** p <0.001** p <0.001*** p <0.001*** p <0.001***

FECD: Fuchs’ Endothelial Cell Corneal Dystrophy; PC.IOL: Posterior chamber intraocular lens; TCT: Total Corneal thickness; CPTR: the quotient of central TCT and peripheral TCT at 4-6 mm from the center; En/DMT: Endothelial/Descemet’s membrane complex (En/DM) thickness. 95% CI: 95 percent confidence interval on the difference between groups. Values are presented as means ± standard deviation for TCT, and as median (range) for En/DMT, CPTR and age.

* P value is calculated using Generalized Estimating Equations (GEE) with logistic link function and exchangeable correlation matrix. ** P value is calculated using GEE with identity link function and exchangeable correlation matrix.

*** Box-Cox analysis identified inverse power transformations as appropriate for attenuating normality and variance heterogeneity problems. P value calculated on the transformed variable using GEE with identity link function and exchangeable correlation matrix.

FECD group

FECD clinical grade9 Grade: N (%) of eyes Phakic: N (%) of eyes Intraocular lens status Pseudophakic: N (%) of eyes Central TCT (µm) Paracentral TCT (µm)

Early-stage (39 eyes)

Late-stage (25 eyes)

1: 18 (46%) 2: 21 (54%)

3: 11 (44%) 4: 14 (56%)

20 (51%)

13 (52%)

19 (49%)

12 (48%)

559 ± 29 570 ± 27

585 ± 38 589 ± 35

p value* Difference (95% CI)*

Not applicable

0.9

25 (6, 43) <0.001 20 (3, 36) <0.019 18 (0.2, Peripheral TCT (µm) 555 ± 39 572 ± 38 0.048 36) 0.01 CPTR 1.01±0.03 1.02±0.02 (-0.004, <0.138 0.03) Central En/DMT (µm) 21±3 29±5 8 (6, 10) <0.001 Paracentral En/DMT (µm) 23±3 30±4 7 (5, 8) <0.001 Peripheral En/DMT (µm) 27±4 33±4 6 (4, 8) <0.001 Table 3: Comparison of the thickness parameters between the early and late-stage FECD eyes. •

FECD: Fuchs’ Endothelial Cell Corneal Dystrophy



TCT: Total Corneal thickness.



En/DMT: Endothelial/Descemet’s membrane complex (En/DM) thickness.



CPTR: the quotient of central TCT and peripheral TCT at 4-6 mm from the center.



95% CI: 95 percent confidence interval on the difference between groups.

Values are presented as means ± standard deviation for TCT, and as median (range) for En/DMT. * Means compared using Generalized Estimating Equations (GEE) with identity link function and exchangeable correlation matrix. Differences, 95% confidence intervals, and p-values were obtained from the GEE model. Age was included as a covariate though it was not statistically significant in any of the models. Box-Cox transformations not necessary for comparing these two groups of eyes with disease.

Table 4: Receiver Operating Characteristic (ROC) curve data which represent the diagnostic performance of regional endothelial/Descemet thickness (En/DMT), and regional total corneal thickness (TCT) in diagnosing Fuchs’ endothelial corneal dystrophy (FECD). All AUC P-values <0.001 for all parameters. In addition to AUCs, we have provided for each parameter sensitivities and specificities, and the parameter cutoffs used to create them.

Detection of FECD (n=104 eyes) Central TCT

Paracentral TCT

CPTR

Central En/DMT

Paracentral En/DMT

Peripheral En/DMT

AUC±SE

0.834±0.039

0.856±0.036

0.937±0.027

0.978±0.012

0.987±0.008

0.996±0.003

( 95% CI)

(0.76, 0.91)

(0.79, 0.93)

(0.88, 0.99)

(0.95, 1.00)

(0.97, 1.00)

(0.99, 1.00)

Sensitivity

77%

81%

94%

92%

94%

94%

Specificity

73%

73%

73%

100%

100%

100%

Cutoff value

538 µm

548 µm

0.97

18 µm

19 µm

20 µm

Discrimination between healthy and early-stage FECD (n=79 eyes) Central TCT

Paracentral TCT

CPTR

Central En/DMT

Paracentral En/DMT

Peripheral En/DMT

AUC±SE

0.801±0.048

0.834±0.044

0.904±0.04

0.972±0.016

0.979±0.013

0.993±0.005

( 95% CI)

(0.71, 0.90)

(0.75, 0.92)

(0.83, 0.98)

(0.94, 1.00)

(0.95, 1.00)

(0.98, 1.00)

Sensitivity

80%

80%

90%

92%

92%

92%

Specificity

70%

59%

88%

97%

97%

93%

Cutoff value

551 µm

560 µm

0.97

18 µm

19 µm

20 µm



FECD = Fuchs’ Endothelial Cell Corneal Dystrophy; AUC = area under the curve; SE = standard error; En/DMT= endothelial/Descemet thickness; TCT= total corneal thickness; CPTR= the quotient of central TCT and peripheral TCT at 4-6 mm from the center; 95% CI: 95 percent confidence interval on the difference between groups. Specificity, sensitivity, and cutoff values are chosen to maximize total diagnostic accuracy (minimize total number of errors).

Precis Regional three-dimensional Endothelium/Descemet’s membrane complex thickness is an objective diagnostic tool that can be potentially used to grade the severity of Fuchs’ Endothelial Cell Corneal Dystrophy.